Neurocysticercosis
Conditions
Interventions
Albendazole alone
Sponsors
REvolution Worldwide S.r.l. Impresa Sociale
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion for screening: • Living in the study area for a continuous period of 3 years • Late onset/acquired epilepsy • Adult aged 18 years and above • Are willing and able to consent to this study • Are willing to undergo diagnostic procedures Inclusion criteria for the treatment study: • Adult aged 18 years and above • Are willing and able to consent to this study • Meet the definitions of active symptomatic NCC • Have late onset of epilepsy or history of seizures, epileptic seizures • Are willing to undergo diagnostic procedures • Are medically stable enough for trial medication to be initiated • Are willing to be hospitalized for 11-20 days to receive treatment for NCC • Are willing to be followed up for one year following receipt of study medication
Exclusion criteria
Exclusion criteria: The participants will be excluded if; • Are pregnant or breastfeeding • Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and/or ventricles) • Have uncontrolled hypertension and/or diabetes • Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions • Have severe immunodeficiency eg. HIV/AIDS or Autoimmune diseases • Already known allergies to albendazole • Subject taking part in another clinical/pharmacological study in the 30 days preceding enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cysts resolution or reduction in both study arms. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Seizure frequency 2. Quality of life 3. Headache severity and frequency 4. Immunological test results | — |
Countries
United Republic of Tanzania
Contacts
Public ContactKabemba Evans Mwape
Senior Lecturer
Outcome results
None listed